| ID | 119180 |
| Author |
Iwatsuki, N
Sakamoto Hospital
Okada, M
Sakamoto Hospital
Ogawa, T
Sakamoto Hospital
Sakamoto, K
Sakamoto Hospital
|
| Keywords | Super-low carbohydrate diet (LCD)
Oral semaglutide (Rybelsus)
Glucagon-like-peptide 1 receptor agonist (GLP1-RA)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
|
| Content Type |
Journal Article
|
| Description | For novel oral hypoglycemic agent (OHA), semaglutide (Rybelsus) has been attracted attention. Patient is 41-year-old hospital staff with obesity, who was pointed out 7.7% of HbA1c with weight 101kg in June 2020. He continued petite-low carbohydrate diet (LCD) for 8 months with weight reduction 3kg. Successively, he applied super-LCD for 7-months and showed 7kg reduction and HbA1c 5.6% in Sept 2021. He took Rybelsus 3mg per os from Mar 2022 and showed 88kg and 5.5% in Nov 2022. LCD brought improvement of ALT from 97 to 27 U/L for 30 months. Thus, LCD and Rybelsus showed satisfactory clinical effect.
|
| Journal Title |
SunText Review of Endocrine Care
|
| ISSN | 27715469
|
| Publisher | SunText Reviews
|
| Volume | 2
|
| Issue | 1
|
| Start Page | 110
|
| Published Date | 2023-04-21
|
| Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
